Following a comprehensive analysis of potentially efficient and safe targets for Ewing Sarcoma, the JCLRI has hypothesized that the generation of CAR T-cells, armed with the iTANK platform and their ability to elicit a multi-targeted attack on solid tumors, can represent an efficacious and safe innovative approach for treatment of metastasized Ewing Sarcoma. Ewing Sarcoma is a difficult to treat cancer indication characterized by ‘immunologically cold’ solid tumors containing an abundance of immunosuppressive cells.
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, today announced to transfer the ownership of patent US 9,017,672 B2 to Elicera Therapeutics AB. The patent is currently out-licensed to Elicera and covers a modified adenovirus that improves gene delivery and tumor cell killing efficiency.